Fox Chase Cancer Center President Robert C. Young, M.D. Receives 2004 Distinguished Service Award for Scientific Leadership from World's Leading Professional Society for Oncologists
PHILADELPHIA (June 5, 2004) -- Fox Chase Cancer Center president Robert C. Young, MD, was honored today for his outstanding dedication to the field of cancer research with the 2004 Distinguished Service Award for Scientific Leadership at the 2004 Annual Meeting of the American Society of Clinical Oncology (ASCO) in New Orleans, La. This special award is presented annually to recognize leaders in the oncology community who have made significant contributions to enhancing the quality of cancer care.
"Your exceptional achievements qualify you as the most deserving candidate for the award," said Charles M. Balch, MD, ASCO executive vice president and chief executive officer, in the award letter to Young. "We applaud you for your outstanding work and dedication."
Young has been president of Fox Chase Cancer Center in Philadelphia since 1988. He is a medical oncologist, internationally recognized for his work in the treatment of lymphoma and ovarian cancer. Young is a past-president of many world-renowned professional organizations, including ASCO, the American Cancer Society and the International Gynecologic Cancer Society.
In addition, he serves on the Board of Scientific Advisors of the National Cancer Institute and the National Cancer Policy Board at the Institute of Medicine. He is past chairman of the board of the National Comprehensive Cancer Network, a nationwide alliance of leading academic cancer centers dedicated to insuring the highest-quality, cost-effective cancer care.
In 2002, Young was the co-recipient with Robert F. Ozols, MD, PhD, of the prestigious 2002 Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research for his research in ovarian cancer. He is the author of more than 400 peer-reviewed publications. Based on the number of medical literature citations, he was one of the top 400 scientist-authors in the U.S. for 1980-1990, according to the Institute for Scientific Information.
A fellow of the American College of Physicians, Young is a member of the American Society of Clinical Investigation. He has served as a member of the subspecialty board on medical oncology for the American Board of Internal Medicine and on the experimental therapeutics study section of the National Cancer Institute.
Young was an associate editor of the Journal of Clinical Oncology from 1987 to 2001 and currently chairs the editorial board of Oncology Times. In 1995, he chaired the General Motors Cancer Research Foundation's Charles F. Kettering Award Selections Committee.
A volunteer with the American Cancer Society for more than 15 years, Young is a past chairman of its medical affairs committee and its research evaluation and targeting committee. He has also served on numerous other national committees. Young remains active with the ACS Pennsylvania Division.
Born in Columbus, Ohio, Young received his B.Sc. degree in zoology in 1960 from Ohio State University and his M.D. in 1965 from Cornell University Medical College. Following his internship at New York Hospital, he completed his residency at NCI and Yale-New Haven Medical Center. He is board-certified in internal medicine, hematology and oncology by the American Board of Internal Medicine.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.